We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Gilead Sciences Inc (GILD) Common Stock USD0.001

Sell:$97.90 Buy:$97.91 Change: $5.60 (6.11%)
NASDAQ:1.51%
Market closed |  Prices as at close on 7 November 2024 | Switch to live prices |
Sell:$97.90
Buy:$97.91
Change: $5.60 (6.11%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 7 November 2024 | Switch to live prices |
Sell:$97.90
Buy:$97.91
Change: $5.60 (6.11%)
Market closed |  Prices as at close on 7 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

Contact details

Address:
333 LAKESIDE DR
FOSTER CITY
94404
United States
Telephone:
+1 (650) 5743000
Website:
https://www.gilead.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GILD
ISIN:
US3755581036
Market cap:
$112.32 billion
Shares in issue:
1.24 billion
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Daniel O'Day
    Chairman of the Board, Chief Executive Officer
  • Andrew Dickinson
    Chief Financial Officer
  • Deborah Telman
    Executive Vice President - Corporate Affairs, General Counsel
  • Johanna Mercier
    Chief Commercial Officer
  • Merdad Parsey
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.